文献速递血脂与心血管预防

Omega-3补充剂与心血管疾病:基于配方的系统评价与荟萃分析及试验序贯分析

Omega-3 supplementation and cardiovascular disease: formulation-based systematic review and meta-analysis with trial sequential analysis.
PubMed 文献 · Heart · 2020-08-20

结果显示每日≤1粒(1g)胶囊与结局无关,而每日2粒可降低心源性死亡(RR 0.55),每日≥3粒可降低心源性死亡、猝死和卒中,但高剂量证据较弱。

要点

  • 每日≤1粒Omega-3胶囊对心血管结局无显著关联,无效边界已跨过。
  • 每日2粒Omega-3胶囊与心源性死亡风险降低相关(RR 0.55,95%CI 0.33-0.90)。
  • 每日≥3粒Omega-3胶囊与心源性死亡、猝死和卒中风险降低相关,但证据强度弱。

核心结论

  • 每日补充<2粒(1g)Omega-3胶囊与心血管疾病结局无关联,未来研究不太可能改变此结论。
  • 高剂量(每日2-4粒1g胶囊)的潜在获益证据较弱,需进一步验证具体配方和适应症。

研究设计与样本

  • 主要分析为按Omega-3剂量(<1、1、2、≥3粒1g胶囊/日)分层的随机效应荟萃分析。

主要发现

  • 每日≤1粒胶囊与所有研究结局均无显著关联,全因死亡和心源性死亡的无效边界已跨过。
  • 每日2粒胶囊显著降低心源性死亡风险(n=3,RR 0.55,95%CI 0.33-0.90,I2=0%)。
  • 每日≥3粒胶囊显著降低心源性死亡风险(n=3,RR 0.82,95%CI 0.68-0.99,I2=0%)。
  • 每日≥3粒胶囊显著降低猝死风险(n=1,RR 0.70,95%CI 0.51-0.97)。
  • 每日≥3粒胶囊显著降低卒中风险(n=2,RR 0.74,95%CI 0.57-0.95,I2=0%)。

临床怎么用

  • 对于心血管疾病预防,每日≤1粒Omega-3胶囊未显示获益,不建议以此剂量常规补充。
  • 高剂量(每日2-4粒1g胶囊)可能降低心源性死亡等风险,但证据较弱,需个体化评估。

局限性

  • 高剂量(每日2-4粒1g胶囊)的证据较弱,需要更多研究重复验证并明确具体配方和适应症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Omega-3 supplements are popular for cardiovascular disease (CVD) prevention. We aimed to assess the association between dose-specific omega-3 supplementation and CVD outcomes. DESIGN: We included double-blind randomised clinical trials with duration ≥1 year assessing omega-3 supplementation and estimated the relative risk (RR) for all-cause mortality, cardiac death, sudden death, myocardial infarction and stroke. Primary analysis was a stratified random-effects meta-analysis by omega-3 dose in 4 a priori defined categories (<1, 1, 2, ≥3 of 1 g capsules/day). Complementary approaches were trial sequential analysis and sensitivity analyses for triglycerides, prevention setting, intention-to-treat analysis, eicosapentaenoic acid, sample size, statin use, study duration. RESULTS: Seventeen studies (n=83 617) were included. Omega-3 supplementation as ≤1 capsule/day was not associated with any outcome under study; futility boundaries were crossed for all-cause mortality and cardiac death. For two capsules/day, we observed a statistically significant reduction of cardiac death (n=3, RR 0.55, 95% CI 0.33 to 0.90, I2=0%); for ≥3 capsules/day we observed a statistically significant reduction of cardiac death (n=3, RR 0.82, 95% CI 0.68 to 0.99, I2=0%), sudden death (n=1, RR 0.70, 95% CI 0.51 to 0.97) and stroke (n=2, RR 0.74, 95% CI 0.57 to 0.95, I2=0%). CONCLUSION: Omega-3 supplementation at <2 1 g capsules/day showed no association with CVD outcomes; this seems unlikely to change from future research. Compared with the robust scientific evidence available for low doses, the evidence for higher doses (2-4 1 g capsules/day) is weak. The emerging postulated benefit from high-dose supplementation needs replication and further evaluation as to the precise formulation and indication.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Rizos EC, Markozannes G, Tsapas A, et al. Omega-3 supplementation and cardiovascular disease: formulation-based systematic review and meta-analysis with trial sequential analysis. Heart. 2020. PMID: 32820013. doi:10.1136/heartjnl-2020-316780

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。